A
Adgero Biopharmaceuticals
Privately-held biopharmaceutical company focused on building a robust pipeline
About Adgero Biopharmaceuticals
Adgero Biopharmaceuticals Holdings, Inc. operated as a privately held biopharmaceutical company, incorporated in Delaware in March 2015. The company focused on developing its proprietary late-stage photodynamic therapy (PDT) platform for the treatment of serious oncology indications, particularly cutaneous cancers. PDT utilizes light-sensitive compounds, known as photosensitizers, which, upon exposure to specific wavelengths of light, generate a form of oxygen that causes localized tumor cell death.
The company's main product candidate was REM-001 Therapy, which comprises a laser light source, a light delivery device, and the drug REM-001. This therapy had shown promising safety and efficacy in four Phase 2/3 clinical studies for treating cutaneous metastatic breast cancer (CMBC) in patients who had previously failed radiation therapy. The existing clinical data for REM-001 indicated an 80% complete response rate for evaluable CMBC lesions across these studies.
In June 2020, Adgero entered into a definitive merger agreement with DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI). The merger was completed in August 2020, with Adgero becoming a wholly-owned subsidiary of DelMar. Following the merger, DelMar was renamed Kintara Therapeutics, Inc. and began trading on the Nasdaq Capital Market under the ticker symbol "KTRA". The strategic combination aimed to create a diversified, publicly-traded oncology company by uniting DelMar's therapeutic candidate, VAL-083, with Adgero's REM-001 therapy. At the time of the merger, Adgero's board included Frank Pilkiewicz, PhD, who served as the CEO.
Source: Dealroom company dataNews
Open roles
Adgero Biopharmaceuticals in the Princeton ecosystem
The Adgero Biopharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Adgero Biopharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Adgero Biopharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

